Description: Longport, Inc. develops, manufactures, markets and sells ultrasound imaging systems. The Company focuses on high resolution medical ultrasound. The Company focuses on providing imaging systems that help in the prevention, assessment and treatment of medical conditions. The Company offers a high resolution ultrasound (HRUS) imaging system, EPISCAN I-200, which utilizes ultrasound to image the skin and underlying soft tissue. EPISCAN I-200 can be connected to a range of interchangeable imaging probes that enable the imaging of the skin and underlying soft tissue at frequencies between 20 megahertz and 50 megahertz. EPISCAN is utilized in a range of clinical applications, as well as in research and development. EPISCAN enables the examination of tissue at a microscopic level. Its technology is used in a range of applications, such as wound assessment and pressure ulcer prevention, dermatology, aesthetics, and research, including validation of processes and products that impact the skin.
Home Page: www.longportinc.com
1620 Baltimore Pike
Chadds Ford,
PA
19317
United States
Phone:
610-361-9100
Officers
| Name | Title |
|---|---|
| Mr. Michael C. Boyd | Chairman & CEO |
| Mr. Paul D. Wilson | Pres, CFO, Director & MD of Longport International - UK |
| Mr. John P. Calabrese | Director of Sales and Marketing |
Exchange: OTCCE
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 8 |